Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Bevacizumab 26Cetuximab 24Fluorouracil 23Leucovorin 22Oxaliplatin 19pembrolizumab 18Specimen Handling 11Irinotecan 10Nivolumab 8Magnetic Resonance Spectroscopy 8atezolizumab 7Biopsy 7Pemetrexed 6Panitumumab 6Cisplatin 6Carboplatin 6trifluridine tipiracil drug combination 5fludarabine 5encorafenib 5HMPL-013 5Gemcitabine 5Folfox protocol 5Standard of Care 4Immunoglobulin G 4Disulfides 4Cyclophosphamide 4zanidatamab 3regorafenib 3fludarabine phosphate 3dehydroftorafur 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colorectal Neoplasms × CA-4948 × 30 days × Clear all
NCT06696768 2026-06-03

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

National Cancer Institute (NCI)

Phase 1 Recruiting
24 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡